A Ligand-observed Mass Spectrometry Approach Integrated into the Fragment Based Lead Discovery Pipeline

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Xin ^a,b   Qin, Shanshan ^a,b   Chen, Shuai ^a,b   Li, Jinlong ^a   Li, Lixin ^b   Wang, Zhongling ^a,b   Wang, Quan ^a,b   Lin, Jianping ^a,b   Yang, Cheng ^a,b   Shui, Wenqing ^a,c  

^a NANKAI UNIVERSITY   (China)

^b High Throughput Molecular Drug Discovery Center   (China)

^c Tianjin Airport Economic Area   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; HEPACIVIRUS; HEPATITIS C; MASS SPECTROMETRY; METABOLISM; PROCEDURES;

DRUG DISCOVERY; HEPACIVIRUS; HEPATITIS C; MASS SPECTROMETRY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84954357339     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08361     Document Type: Article

References (61)

1. Hajduk, P. J. & Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discovery 6, 211-219 (2007).
2. Chessari, G. &Woodhead, A. J. From fragment to clinical candidate - a historical perspective. Drug Discov. Today 14, 668-675 (2009).
3. Erlanson, D. A. et al. Site-directed ligand discovery. Proc. Natl. Acad. Sci. 97, 9367-9372 (2000).
4. Carr, R. A., Congreve, M., Murray, C. W. & Rees, D. C. Fragment-based lead discovery: leads by design. Drug Discov. Today 10, 987-992 (2005).
5. Congreve, M., Murray, C. W., Carr, R. & Rees, D. C. Fragment-based lead discovery. Annu. Rep. Med. Chem. 42, 431 (2007).
6. Whittaker, M., Law, R. J., Ichihara, O., Hesterkamp, T. & Hallett, D. Fragments: past, present and future. Drug Discov. Today: Technologies 7, e163-e171 (2010).
7. Sancineto, L., Massari, S., Iraci, N. & Tabarrini, O. From Small to Powerful: The Fragments Universe and its "Chem-Appeal". Curr. Med. Chem. 20, 1355-1381 (2013).
8. Mashalidis, E. H.,͆ledź, P., Lang, S. & Abell, C. A three-stage biophysical screening cascade for fragment-based drug discovery. Nat. Protoc. 8, 2309-2324 (2013).
9. Dalvit, C. NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov. Today 14, 1051-1057(2009).
10. Pellecchia, M. et al. Perspectives on NMR in drug discovery: a technique comes of age. Nat. Rev. Drug Discovery 7, 738-745 (2008).
11. Geitmann, M. et al. Identification of a Novel Scaffold for Allosteric Inhibition of Wild Type and Drug Resistant HIV-1 Reverse Transcriptase by Fragment Library Screening. J. Med. Chem. 54, 699-708 (2011).
12. Torres, F. E., Recht, M. I., Coyle, J. E., Bruce, R. H. & Williams, G. Higher throughput calorimetry: opportunities, approaches and challenges. Curr. Opin. Struc. Biol. 20, 598-605 (2010).
13. Ciulli, A.,Williams, G., Smith, A. G., Blundell, T. L. & Abell, C. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. J. Math. Chem. 49, 4992-5000 (2006).
14. Jhoti, H., Cleasby, A., Verdonk, M. & Williams, G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr. Opin. Chem. Biol. 11, 485-493(2007).
15. Hartshorn, M. J. et al. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 48, 403-413 (2005).
16. Maple, H. J. et al. Automated protein-ligand interaction screening by mass spectrometry. J. Med. Chem. 55, 837-851 (2012).
17. Silvestre, H. L., Blundell, T. L., Abell, C. & Ciulli, A. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc. Natl. Acad. Sci. 110, 12984-12989 (2013).
18. Kelly, M. A., McLellan, T. J. & Rosner, P. J. Strategic use of affinity-based mass spectrometry techniques in the drug discovery process. Anal. Chem. 74, 1-9 (2002).
19. Eldridge, G. R. et al. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Anal. Chem. 74, 3963-3971 (2002).
20. Duffell, K. M. et al. A Nanoelectrospray Ionisation Mass Spectrometric Study of Mycobacterium tuberculosis CYP121-Ligand Interactions. Anal. Chem. 85, 5707-5714(2013).
21. Liu, L., Kitova, E. N. & Klassen, J. S. Quantifying protein-fatty acid interactions using electrospray ionization mass spectrometry. J. Am. Chem. Soc. 22, 310-318 (2011).
22. Zhou, H. et al. Screening and Determination for Potential a-Glucosidase Inhibitors from Leaves of Acanthopanax senticosus Harms by Using UF-LC/MS and ESI-MS (n). Phytochem. Anal. 23, 315 (2012).
23. Hofstadler, S. A. & Sannes-Lowery, K. A. Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes. Nat. Rev. Drug Discovery 5, 585-595 (2006).
24. Vivat Hannah, V., Atmanene, C., Zeyer, D., Van Dorsselaer, A. & Sanglier-Cianférani, S. Native MS: an 'ESI' way to support structure-and fragment-based drug discovery. Future Med. Chem. 2, 35-50 (2010).
25. Chen, X. et al. Identification of Inhibitors of the Antibiotic-Resistance Target New Delhi Metallo-b-lactamase 1 by both Nanoelectrospray Ionization Mass Spectrometry and Ultrafiltration Liquid Chromatography/Mass Spectrometry Approaches. Anal. Chem. 85, 7957-7965 (2013).
26. Clark, S. M. & Konermann, L. Determination of ligand-protein dissociation constants by electrospray mass spectrometry-based diffusion measurements. Anal. Chem. 76, 7077-7083 (2004).
27. Peschke, M., Verkerk, U. H. & Kebarle, P. Features of the ESI mechanism that affect the observation of multiply charged noncovalent protein complexes and the determination of the association constant by the titration method. J. Am. Soc. Mass. Spectrom. 15, 1424-1434 (2004).
28. Mathur, S., Badertscher, M., Scott, M. & Zenobi, R. Critical evaluation of mass spectrometric measurement of dissociation constants: accuracy and crossvalidation against surface plasmon resonance and circular dichroism for the calmodulin-melittin system. Phys. Chem. Chem. Phys. 9, 6187-6198 (2007).
29. Mulabagal, V. & Calderón, A. I. Development of binding assays to screen ligands for Plasmodium falciparum thioredoxin and glutathione reductases by ultrafiltration and liquid chromatography/mass spectrometry. J. Chromatogr. B 878, 987-993 (2010).
30. Choi, Y. et al. Screening Natural Products for Inhibitors of Quinone Reductase-2 Using Ultrafiltration LC2 MS. Anal. Chem. 83, 1048-1052 (2010).
31. Whitehurst, C. E. et al. Application of Affinity Selection-Mass Spectrometry Assays to Purification and Affinity-Based Screening of the Chemokine Receptor CXCR4. Comb. Chem. High Throughput Screen. 15, 473-485 (2012).
32. Meiby, E., Knapp, S., Elkins, J. M. & Ohlson, S. Fragment screening of cyclin Gassociated kinase by weak affinity chromatography. Anal. Bioanal. Chem. 404, 2417-2425 (2012).
33. Duong-Thi, M.-D., Bergström, M., Fex, T., Isaksson, R. & Ohlson, S. Highthroughput fragment screening by affinity LC-MS. J. Biomol. Screen. 18, 160-171 (2013).
34. van Breemen, R. B. et al. Pulsed ultrafiltration mass spectrometry: A new method for screening combinatorial libraries. Anal. Chem. 69, 2159-2164 (1997).
35. Zhao, Y.-Z. et al. Screening solution-phase combinatorial libraries using pulsed ultrafiltration/electrospray mass spectrometry. J. Med. Chem. 40, 4006-4012 (1997).
36. Yang, Z. et al. An ultrafiltration high-performance liquid chromatography coupled with diode array detector and mass spectrometry approach for screening and characterising tyrosinase inhibitors from mulberry leaves. Anal. Chim. Acta 719, 87-95 (2012).
37. Munigunti, R., Mulabagal, V. & Calderón, A. I. Screening of natural compounds for ligands toPfTrxR by ultrafiltration and LC-MS based binding assay. J. Pharm. Biomed. Anal. 55, 265-271 (2011).
38. Sofia, M. J., Chang, W., Furman, P. A., Mosley, R. T. & Ross, B. S. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNAdependent RNA-polymerase. J. Med. Chem. 55, 2481-2531 (2012).
39. Chinnaswamy, S., Cai, H. & Kao, C. An update on small molecule inhibitors of the HCV NS5B polymerase: effects on RNA synthesis in vitro and in cultured cells, and potential resistance in viral quasispecies. Virus Adap. and Treat. 2, 73-89 (2010).
40. Eastman, K. J. et al. Identification of a novel series of potent HCV NS5B Site I inhibitors. Bioorg. Med. Chem. Lett. 24, 1993-1997 (2014).
41. Talamas, F. X. et al. DeNovo Fragment Design: A Medicinal Chemistry Approach to Fragment-Based Lead Generation. J. Med. Chem. 56, 3115-3119 (2013).
42. Stammers, T. A. et al. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors. Bioorg. Med. Chem. Lett. 23, 2585-2589 (2013).
43. Antonysamy, S. S. et al. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. Bioorg. Med. Chem. Lett. 18, 2990-2995 (2008).
44. Lo, M.-C. et al. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 332, 153-159 (2004).
45. McDonnell, P. A. et al. Assessing compound binding to the Eg5 motor domain using a thermal shift assay. Anal. Biochem. 392, 59-69 (2009).
46. Barelier, S., Pons, J., Gehring, K., Lancelin, J.-M. & Krimm, I. Ligand specificity in fragment-based drug design. J. Med. Chem. 53, 5256-5266 (2010).
47. Barelier, S. & Krimm, I. Ligand specificity, privileged substructures and protein druggability from fragment-based screening. Curr. Opin. Chem. Biol. 15, 469-474 (2011).
48. Goyal, S. et al. VAPC, an human endogenous inhibitor for hepatitis Cvirus (HCV) infection, is intrinsically unstructured but forms a "fuzzy complex" with HCV NS5B. PLoS One 7, e40341 (2012).
49. Kreatsoulas, C. & Narayan, K. Algorithms for the automated selection of fragment-like molecules using single-point surface plasmon resonance measurements. Anal. Biochem. 402, 179-184 (2010).
50. Steitz, T. A. DNA Polymerases: Structural Diversity and Common Mechanisms. J. Biol. Chem. 274, 17395-17398 (1999).
51. Talele, T. T. Multiple allosteric pockets of HCV NS5B polymerase and its inhibitors: a structure-based insight. Curr. Bioact. Compd. 4, 86-109 (2008).
52. Burton, G. et al. Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture. Bioorg. Med. Chem. Lett. 15, 1553-1556 (2005).
53. Burton, G. Acyl Pyrrolidine Inhibitors of HCV RNA-Dependent RNA Polymerase to Identify a Molecule with Replicon Antiviral Activity. Bioorg. Med. Chem. Lett. 17, 1930-1933 (2007).
54. Powers, J. P. et al. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. J. Med. Chem. 49, 1034-1046 (2006).
55. Munigunti, R. & Calderón, A. I. Development of liquid chromatography/mass spectrometry based screening assay for PfTrxR inhibitors using relative quantitation of intact thioredoxin. Rapid Commun. Mass Spectrom. 26, 2051-2056 (2012).
56. Yang, Z. et al. An ultrafiltration high-performance liquid chromatography coupled with diode array detector and mass spectrometry approach for screening and characterising tyrosinase inhibitors from mulberry leaves. Anal. Chim. Acta 719, 87-95 (2012).
57. Drinkwater, N. et al. Fragment-based screening by X-ray crystallography,MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine Nmethyltransferase) inhibitors. Biochem. J. 431, 51-61 (2010).
58. Comess, K. M. et al. An Ultraefficient Affinity-Based High-Throughout Screening Process: Application to Bacterial Cell Wall Biosynthesis Enzyme MurF. J. Biomol. Screen. 11, 743-754 (2006).
59. Murray, C. W. et al. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J. Med. Chem. 53, 5942-5955 (2010).
60. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235-242 (2011).
61. Bressanelli, S. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. 96, 13034-13039 (1999).